SIRT1调控足细胞损伤诱发蛋白尿机制研究进展

doi:10.11958/20253032

天津医药 ›› 2026, Vol. 54 ›› Issue (5): 556-560.doi: 10.11958/20253032

• 综述 • 上一篇

SIRT1调控足细胞损伤诱发蛋白尿机制研究进展

贺佳¹(), 窦一田^2△()

¹ 天津中医药大学第一附属医院，国家中医针灸临床医学研究中心（邮编 300381）
² 天津中医药大学第一附属医院肾病科

收稿日期:2025-09-02 修回日期:2026-01-09 出版日期:2026-05-15 发布日期:2026-05-13
通讯作者: ^△E-mail：hczar1745@163.com
作者简介:贺佳（2000），女，硕士在读，主要从事肾脏疾病的诊疗方面研究。E-mail：381992613@qq.com
基金资助:
国家自然科学基金面上资助项目(82474450);天津市卫生健康委员会中医中西医结合科研课题(2023201);天津市名中医传承工作室建设项目(tjmzy2404);河北省中医药管理局科研计划项目(T2025115);绍兴市基础公益类计划项目(2023A14045);绍兴市级科技计划项目

Research progress on the mechanism of SIRT1 in regulating podocyte injury-induced proteinuria

HE Jia¹(), DOU Yitian^2△()

¹ First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin 300381, China
² Department of Nephrology, the First Affiliated Hospital of Tianjin Medical University of Traditional Chinese Medicine

Received:2025-09-02 Revised:2026-01-09 Published:2026-05-15 Online:2026-05-13
Contact: ^△E-mail：hczar1745@163.com

贺佳, 窦一田. SIRT1调控足细胞损伤诱发蛋白尿机制研究进展[J]. 天津医药, 2026, 54(5): 556-560.

HE Jia, DOU Yitian. Research progress on the mechanism of SIRT1 in regulating podocyte injury-induced proteinuria[J]. Tianjin Medical Journal, 2026, 54(5): 556-560.

摘要/Abstract

摘要：

蛋白尿作为肾脏疾病的早期诊断依据与疾病进展重要临床指标，其发生与足细胞损伤相关。沉默信息调节因子Sirtuin 1（SIRT1）是一种高度保守的多功能蛋白，既可作为烟酰胺腺嘌呤二核苷酸依赖性脱乙酰酶，通过对转录因子去乙酰化进程的调控影响多种生物学过程；亦可凭借其非酶活性机制参与信号转导，二者共同构成其调控足细胞稳态的分子基础。SIRT1与足细胞损伤密切关联，其可通过调控巨噬细胞功能、自噬、脂质代谢、氧化应激与上皮-间充质转化进程并维持线粒体稳态，从而保护足细胞，减少蛋白尿发生，延缓肾损伤进展。该文就SIRT1调控足细胞损伤诱发蛋白尿机制进行综述，以期为更深入的机制研究及更广泛的临床应用提供参考。

关键词: 抗衰老酶1, 足细胞, 蛋白尿

Abstract:

Proteinuria is an important clinical indicator for the early diagnosis of kidney disease and disease progression, and its occurrence is related to podocyte injury. Sirtuin 1 ( SIRT1 ) is a highly conserved multifunctional protein that acts as a nicotinamide adenine dinucleotide-dependent deacetylase and affects a variety of biological processes by regulating the deacetylation process of transcription factors. It can also participate in signal transduction by virtue of its non-enzymatic activity mechanism, which together constitute the molecular basis for its regulation of podocyte homeostasis. Relevant studies have shown that SIRT1 is closely related to podocyte injury. It regulates macrophage function, autophagy process, lipid metabolism, oxidative stress and epithelial-mesenchymal transition (EMT) process, and maintains mitochondrial homeostasis, thereby protecting podocytes, reducing proteinuria and delaying the progression of renal injury. Here is to make a preliminary review of the research on the related mechanisms in recent years, in order to provide reference for the related clinical and basic research. This article reviews the mechanism of SIRT1 regulating podocyte injury-induced proteinuria, in order to provide reference for further mechanism research and wider clinical application.

Key words: sirtuin 1, podocytes, proteinuria

中图分类号:

R692.6

参考文献 48

[1]	BOI R, BERGWALL L, EBEFORS K, et al. Podocyte geranylgeranyl transferase type-I is essential for maintenance of the glomerular filtration barrier[J]. J Am Soc Nephrol, 2023, 34(4):641-655. doi:10.1681/asn.0000000000000062.
[2]	LUO Z, CHEN Z, HU J, et al. Interplay of lipid metabolism and inflammation in podocyte injury[J]. Metabolism, 2024, 150:155718. doi:10.1016/j.metabol.2023.155718.
[3]	LIAO M C, LO C S, PANG Y C, et al. Heterogeneous nuclear ribonucleoprotein F deficiency in mouse podocyte promotes podocytopathy mediated by methyltransferase-like 14 nuclear translocation resulting in Sirtuin 1 gene inhibition[J]. Transl Res, 2024, 267:1-9. doi:10.1016/j.trsl.2024.01.002.
[4]	TANG Y, WAN F, TANG X, et al. Celastrol attenuates diabetic nephropathy by upregulating SIRT1-mediated inhibition of EZH2 related WNT/β-catenin signaling[J]. Int Immunopharmacol, 2023, 122:110584. doi: 10.1016/j.intimp.2023.110584.
[5]	LI L, ZOU J, ZHOU M, et al. Phenylsulfate-induced oxidative stress and mitochondrial dysfunction in podocytes are ameliorated by astragaloside Ⅳ activation of the SIRT1/PGC1α /NRF1 signaling pathway[J]. Biomed Pharmacother, 2024, 177:117008. doi:10.1016/j.biopha.2024.117008.
[6]	TAKAHASHI K, SATO E, YAMAKOSHI S, et al. Nicotinamide ameliorates podocyte injury and albuminuria in adriamycin-induced nephropathy[J]. Am J Physiol Renal Physiol, 2025, 328(4):F501-f516. doi:10.1152/ajprenal.00297.2024.
[7]	XIE L, CHENG Y, DU W, et al. Activation of GPER1 in macrophages ameliorates uuo-induced renal fibrosis[J]. Cell Death Dis, 2023, 14(12):818. doi:10.1038/s41419-023-06338-2.
[8]	MA Y, CHEN Y, XU H, et al. The influence of angiopoietin-like protein 3 on macrophages polarization and its effect on the podocyte EMT in diabetic nephropathy[J]. Front Immunol, 2023, 14:1228399. doi:10.3389/fimmu.2023.1228399.
[9]	CAO Y, XIONG J, GUAN X, et al. Paeoniflorin suppresses kidney inflammation by regulating macrophage polarization via KLF4-mediated mitophagy[J]. Phytomedicine, 2023, 116:154901. doi:10.1016/j.phymed.2023.154901.
[10]	KUANG G, ZHAO Y, WANG L, et al. Astragaloside Ⅳ alleviates acute hepatic injury by regulating macrophage polarization and pyroptosis via activation of the AMPK/SIRT1 signaling pathway[J]. Phytother Res, 2025, 39(2):733-746. doi:10.1002/ptr.8403.
[11]	ZHAO X, LI M, LU Y, et al. SIRT1 inhibits macrophage polarization and inflammation in gouty arthritis by inhibiting the MAPK/NF-κB/AP-1 pathway and activating the NRF2/HO-1 pathway[J]. Inflamm Res, 2024, 73(7):1173-1184. doi:10.1007/s00011-024-01890-9.
[12]	KE G, CHEN X, LIAO R, et al. Receptor activator of NF-κB mediates podocyte injury in diabetic nephropathy[J]. Kidney Int, 2021, 100(2):377-390. doi:10.1016/j.kint.2021.04.036.
[13]	LV C, CHENG T, ZHANG B, et al. Triptolide protects against podocyte injury in diabetic nephropathy by activating the NRF2//HO-1 pathway and inhibiting the NLRP3 inflammasome pathway[J]. Ren Fail, 2023, 45(1):2165103. doi:10.1080/0886022x.2023.2165103.
[14]	HE J, CUI J, SHI Y, et al. Astragaloside Ⅳ attenuates high-glucose-induced impairment in diabetic nephropathy by increasing Klotho expression via the NF-κB/NLRP3 axis[J]. J Diabetes Res, 2023, 2023:7423661. doi:10.1155/2023/7423661.
[15]	HE S, WANG Y, LIU J, et al. Activating SIRT1 deacetylates NF-κB P65 to alleviate liver inflammation and fibrosis via inhibiting NLRP3 pathway in macrophages[J]. Int J Med Sci, 2023, 20(4):505-519. doi:10.7150/ijms.77955.
[16]	JIANG M, ZHAO M, BAI M, et al. SIRT1 alleviates aldosterone-induced podocyte injury by suppressing mitochondrial dysfunction and NLRP3 inflammasome activation[J]. Kidney Dis (Basel), 2021, 7(4):293-305. doi:10.1159/000513884.
[17]	YANG Q, YANG S, LIANG Y, et al. UCP2 deficiency impairs podocyte autophagy in diabetic nephropathy[J]. Biochim Biophys Acta Mol Basis Dis, 2023, 1869(5): 166705. doi:10.1016/j.bbadis.2023.166705.
[18]	LI D, YUAN S, DENG Y. Interference in the nutrient-sensing and inflammatory signaling pathways by renal autophagy activation in mice with late stage diabetic nephropathy[J]. Int Urol Nephrol, 2024, 56(1):303-311. doi:10.1007/s11255-023-03687-x.
[19]	STANIGUT A M, TUTA L, PANA C, et al. Autophagy and mitophagy in diabetic kidney disease-a literature review[J]. Int J Mol Sci, 2025, 26(2):806. doi:10.3390/ijms26020806.
[20]	JIN D, ZHAO Y, SUN Y, et al. Jiedu tongluo baoshen formula enhances renal tubular epithelial cell autophagy to prevent renal fibrosis by activating SIRT1/LKB1/AMPK pathway[J]. Biomed Pharmacother, 2023, 160:114340. doi:10.1016/j.biopha.2023.114340.
[21]	LI Y, AN M, FU X, et al. Bushen wenyang huayu decoction inhibits autophagy by regulating the SIRT1-FOXO-1 pathway in endometriosis rats[J]. J Ethnopharmacol, 2023, 308:116277. doi:10.1016/j.jep.2023.116277.
[22]	TAO H, YU L. MTERF1 regulates podocyte mitochondrial DNA replication impairment and mitochondrial dysfunction in diabetic nephropathy through the AMPK/MTOR pathway[J]. Ann Clin Lab Sci, 2025, 55(5):663-671.
[23]	LIU H, WANG J, YUE G, et al. Placenta-derived mesenchymal stem cells protect against diabetic kidney disease by upregulating autophagy-mediated SIRT1/FOXO 1 pathway[J]. Ren Fail, 2024, 46(1):2303396. doi:10.1080/0886022x.2024.2303396.
[24]	WANG F, LI R, ZHAO L, et al. Resveratrol ameliorates renal damage by inhibiting oxidative stress-mediated apoptosis of podocytes in diabetic nephropathy[J]. Eur J Pharmacol, 2020, 885:173387. doi:10.1016/j.ejphar.2020.173387.
[25]	HUANG F, HUANG S, SUN K, et al. Protective effect of compound K against podocyte injury in chronic kidney disease by maintaining mitochondrial homeostasis[J]. Sci Rep, 2025, 15(1):435. doi:10.1038/s41598-024-84704-6.
[26]	XIA C, ZHANG J, CHEN H, et al. Kaempferol improves mitochondrial homeostasis via mitochondrial dynamics and mitophagy in diabetic kidney disease[J]. Int Immunopharmacol, 2025, 162:115121. doi:10.1016/j.intimp.2025.115121.
[27]	LIU Y, YANG H, LUO N, et al. An FGR kinase inhibitor attenuates sepsis-associated encephalopathy by ameliorating mitochondrial dysfunction,oxidative stress,and neuroinflammation via the SIRT1/PGC-1α signaling pathway[J]. J Transl Med, 2023, 21(1):486. doi:10.1186/s12967-023-04345-7.
[28]	AI Z, YUAN D, DONG R, et al. Rostellularia procumbens (L) nees. Extract attenuates adriamycin-induced nephropathy by maintaining mitochondrial dynamics balance via SIRT1/PGC-1α signaling pathway activation[J]. J Ethnopharmacol, 2025, 340:119297. doi:10.1016/j.jep.2024.119297.
[29]	ZHANG T, CHI Y, KANG Y, et al. Resveratrol ameliorates podocyte damage in diabetic mice via SIRT1/PGC-1α mediated attenuation of mitochondrial oxidative stress[J]. J Cell Physiol, 2019, 234(4):5033-5043. doi:10.1002/jcp.27306.
[30]	RUI Y, GUO Y, HE L, et al. SIRT1/PGC-1α-mediated mitophagy participates the improvement roles of BMAL1 in podocytes injury in diabetic nephropathy:evidences from in vitro experiments[J]. Eur J Med Res, 2025, 30(1):29. doi:10.1186/s40001-025-02280-5.
[31]	HAN X, WANG J, LI R, et al. Placental mesenchymal stem cells alleviate podocyte injury in diabetic kidney disease by modulating mitophagy via the SIRT1-PGC-1α-TFAM pathway[J]. Int J Mol Sci, 2023, 24(5):4696. doi:10.3390/ijms24054696.
[32]	WANG Y, LIU T, WU Y, et al. Lipid homeostasis in diabetic kidney disease[J]. Int J Biol Sci, 2024, 20(10):3710-3724. doi:10.7150/ijbs.95216.
[33]	QU H, LIU X, ZHU J, et al. DOCK5 deficiency promotes proteinuric kidney diseases via modulating podocyte lipid metabolism[J]. Adv Sci (Weinh), 2024, 11(11):e2306365. doi:10.1002/advs.202306365.a.
[34]	YANG M, QIN W, DAI Q, et al. 18β-glycyrrhetinic acid mitigates lipotoxicity-induced premature senescence of tubular epithelial cells by activating SIRT1-TFEB signaling[J]. Phytomedicine, 2025, 143:156846. doi:10.1016/j.phymed.2025.156846.
[35]	FU Y, SUN Y, WANG M, et al. Elevation of JAML promotes diabetic kidney disease by modulating podocyte lipid metabolism[J]. Cell Metab, 2020, 32(6):1052-1062.e1058. doi:10.1016/j.cmet.2020.10.019.
[36]	WANG Q, ZHAO B, ZHANG J, et al. Faster lipid β-oxidation rate by acetyl-coA carboxylase 2 inhibition alleviates high-glucose-induced insulin resistance via SIRT1/PGC-1α in human podocytes[J]. J Biochem Mol Toxicol, 2021, 35(7):e22797. doi:10.1002/jbt.22797.
[37]	LU W. Sulforaphane regulates ANG Ⅱ-induced podocyte oxidative stress injury through the NRF2-KEAP1/HO-1/ROS pathway[J]. Ren Fail, 2024, 46(2):2416937. doi:10.1080/0886022x.2024.2416937.
[38]	ZHENG C M, HOU Y C, LIAO M T, et al. Potential role of molecular hydrogen therapy on oxidative stress and redox signaling in chronic kidney disease[J]. Biomed Pharmacother, 2024, 176:116802. doi:10.1016/j.biopha.2024.116802.
[39]	LI H R, LIU Q, ZHU C L, et al. Β-nicotinamide mononucleotide activates NAD+/SIRT1 pathway and attenuates inflammatory and oxidative responses in the hippocampus regions of septic mice[J]. Redox Biol, 2023, 63:102745. doi:10.1016/j.redox.2023.102745.
[40]	FENG J, BAO L, WANG X, et al. Low expression of HIV genes in podocytes accelerates the progression of diabetic kidney disease in mice[J]. Kidney Int, 2021, 99(4):914-925. doi:10.1016/j.kint.2020.12.012.
[41]	DAN HU Q, WANG H L, LIU J, et al. BTG2 promotes focal segmental glomerulosclerosis via SMAD3-dependent podocyte-mesenchymal transition[J]. Adv Sci (Weinh), 2023, 10(32):e2304360. doi:10.1002/advs.202304360.
[42]	WANG X, GAO Y, TIAN N, et al. Astragaloside IV inhibits glucose-induced epithelial-mesenchymal transition of podocytes through autophagy enhancement via the SIRT1-NF-κB P65 axis[J]. Sci Rep, 2019, 9(1):323. doi:10.1038/s41598-018-36911-1.
[43]	LI M, WU Z, GAO W, et al. Polysaccharide H-1-2 ameliorates high glucose-induced podocyte dysfunction by suppressing epithelial-to-mesenchymal transition via restoration of SIRT1 in vivo and in vitro[J]. Tohoku J Exp Med, 2023, 260(1):35-45. doi:10.1620/tjem.2023.J015.
[44]	ZHANG Z, TANG C M, YU W Z, et al. Podocyte proteomics revealed hUCMSC-exosomes ameliorate diabetic kidney disease through inhibiting TALIN-1 mediated EMT[J]. J Proteome Res, 2025, 24(9):4767-4779. doi:10.1021/acs.jproteome.5c00523.
[45]	王凯, 孙林成, 余婓, 等. 番泻叶苷A对糖尿病肾病大鼠足细胞自噬的影响[J]. 西北药学杂志, 2024, 39(1):78-84.
	WANG K, SUN L C, YU F, et al. Influence of sennoside A on podocyte auto[phagy in diabetic nephropathy rats[J]. Northwest Pharm J, 2024, 39(1):78-84.
[46]	HO L, TSANG Y, HUNG H, et al. SIRTUIN 1 inhibits NLRP3 inflammasome activation through protein-protein interaction[J]. Life Sci, 2026:390:124260. doi:10.1016/j.lfs.2026.124260.
[47]	LI X, MA T, DENG X, et al. HOXA2 exerts anti-renal fibrosis effects through reducing endoplasmic reticulum stress via the upregulation of SIRT1[J]. Commun Biol, 2025, 9(1):174. doi:10.1038/s42003-025-09453-2.
[48]	YANG J, WANG Z X, FANG L, et al. Atractylodes lancea and magnolia officinalis combination protects against high fructose-impaired insulin signaling in glomerular podocytes through upregulating SIRT1 to inhibit P53-driven MIR-221[J]. J Ethnopharmacol, 2023, 300:115688. doi:10.1016/j.jep.2022.115688.

SIRT1调控足细胞损伤诱发蛋白尿机制研究进展

Research progress on the mechanism of SIRT1 in regulating podocyte injury-induced proteinuria

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

[1]	孔翠文, 路延双, 孙丽萍, 于芬芬. LncRNA SNHG14靶向miR-30a-5p对高糖诱导的足细胞损伤的影响[J]. 天津医药, 2025, 53(9): 903-909.
[2]	李硕, 张云鹏, 黄艳, 曹美然, 贾兰芳, 胡桂才, 黄兰, 段书众. 系统性免疫炎症指数与IgA肾病患者临床病理特征的关系[J]. 天津医药, 2025, 53(9): 932-936.
[3]	李冰心, 许军英, 张雅茹, 周小兵. 冬虫夏草通过调控AMPK/mTOR通路保护高糖诱导的足细胞损伤[J]. 天津医药, 2025, 53(3): 225-229.
[4]	任宇, 李慧宇, 马亚杰, 张钰玲, 季倩. BOLD联合mDixon Quant定量评估2型糖尿病患者早期肾脏氧代谢和铁沉积的效果[J]. 天津医药, 2025, 53(11): 1197-1203.
[5]	李勇, 苏亚坤, 张宏博, 李原, 李占虎, 闫小菊. 原发性高血压早期肾损害患者血清白脂素水平的临床意义[J]. 天津医药, 2024, 52(6): 609-613.
[6]	解有成, 王菲, 徐进, 于晓辉. SIRT1在糖尿病心肌病发病中的研究进展[J]. 天津医药, 2024, 52(4): 443-448.
[7]	白梦刻, 杨晓青, 梅晓峰, 李金刚, 张秋爽, 黄岩杰. 伴血脂异常的儿童IgA血管炎肾炎尿蛋白和病理特征分析[J]. 天津医药, 2023, 51(7): 751-755.
[8]	董彦, 崔剑, 张丽, 郎楠, 王建波, 于志强. 乌司他丁缓解子痫前期大鼠高血压、蛋白尿和炎症反应的实验研究[J]. 天津医药, 2022, 50(9): 943-947.
[9]	程维丽, 陈晓攀, 齐媛媛, 文璐, 王晓阳. C/EBPβ通过pim-1介导足细胞损伤的作用机制[J]. 天津医药, 2022, 50(3): 230-235.
[10]	曹磊, 胡恩赑, 李晓楠. vWF和vWF裂解酶水平对糖尿病肾病的影响[J]. 天津医药, 2022, 50(2): 190-194.
[11]	张宏红, 谢琳, 盛思琪, 卢冠军, 姜怡邓, 杨安宁, 李桂忠, △. FoxO1在同型半胱氨酸诱导的肾脏足细胞损伤及凋亡中的作用研究[J]. 天津医药, 2022, 50(1): 53-58.
[12]	彭雷, 林英英, 汪伟, 姚琪, 李贵森, 张萍△. 原发性肾病综合征患者肾组织中Angptl4与足细胞损伤及蛋白尿的相关性研究[J]. 天津医药, 2021, 49(9): 958-962.
[13]	饶超峰, 薛笑楠, 朱明英, 罗富里. 巨噬细胞外泌体通过抑制自噬诱导高血糖对肾小球足细胞的损伤作用 #br#[J]. 天津医药, 2021, 49(2): 119-125.
[14]	王新念, 翟亚玲, 姚星辰, 盛晓笑, 张文惠, 赵占正. 微量蛋白尿合并肾功能不全的IgA肾病患者临床病理特点及预后分析[J]. 天津医药, 2021, 49(11): 1175-1179.
[15]	陈翔, 黄莹, 龙春艺, 廖品琥. miR-21调控PTEN/AKT通路影响LPS诱导下足细胞中MMP-2和MMP-9表达[J]. 天津医药, 2019, 47(3): 230-234.